Biocept, Inc. · OTC:BIOCQ
Biocept — IPO Roadshow (July 2018)
57 slides from Biocept's IPO roadshow presentation, Jul 11, 2018
Slide 1: Forward-Looking Statements
Forwar d - Lo o ki n g Stateme n ts Th i s p r e s e ntation cont a i n s , and any a cc o m pany i n g or a l pre s e ntation wo u l d no do u bt c o n ta i n , f orward-look i ng statement s , with i n the m ea n ing o f t he P r i vate S e c ur i t i es L i t i g a t i on R e f orm Ac t o f 19 9
Slide 2: Biocept: Completing the Answer
Biocept Completing the Answer™
Slide 3: Company overview
CLIA – CAP accredited laboratory located in San Diego Patented technology used for liquid biopsy in cancer Providing actionable information to help physicians make treatment decisions NASDAQ: BIOC, Listed 2014 Market Cap: +/- $15M Shares Out: 68.5M ADTV: ~1,500K High concordance to tissue biopsy Col
Slide 4: Investment Highlights
In v e s tment High l ig h ts Liquid Biopsy Market Estimated at $10+ Billion ▪ Potential to improve cancer patient outcomes ▪ Advantages of a simple blood test vs. tissue biopsy (convenience, repeatability, feasibility benefits, reduced cost and fewer complications) Test Menu Focused Only on Actiona
Slide 5: Anticipated Milestones
Anti c i p at e d Mil e s t o n es Ne x t 1 2 Months ✓ Inc r ea s e mar k et pen e tration into eme r ging liquid biop s y s e gment ✓ En t er into str a tegic c o mmer c ial and tech n ology pa r tner s h ips – Global and U.S. ✓ S ign addit i onal E mpower TC agreements with pathologis t s and majo
Slide 6: Patients Diagnosed with Cancer in the US
Patients Diagnosed with Cancer in the US
Slide 7: Estimated New Cancer Cases and Deaths
Estimated New Cases Prostate 161,360 19% Breast 252,710 30% Lung & bronchus 116,990 14% Lung & bronchus 105,510 12% Colon & rectum 71,420 9% Colon & rectum 64,010 8% Urinary bladder 60,490 7% Uterine corpus 61,380 7% Melanoma of the skin 52,170 6% Thyroid 42,470 5% Kidney & renal pelvis 40,610 5% Me
Slide 8: Our Team has a Deep & Successful History of Commercializing Innovation
Our Team has a Deep & Successful History of Commercializing Innovation Michael Nall President & CEO • 25+ years in healthcare sales, marketing and commercial operations • 16 years in cancer diagnostics and genomics • Most recently General Manager N. American Sales and Marketing for Clarient — a GE H
Slide 9: Biocept is Guided by a Board of Visionaries & Scientific Influencers
B i oce p t is Guid e d by a B o ard of V is i on a ries & Sc i entific In f l u enc e rs Board of Directors Clinical Advisory Board David F. Hale Bruce E. Gerhardt, CPA Lee Schwartzberg, MD David Carbone, MD Chairman Director, Member Audit Committee Chief, Division of Hematology Oncology; Director,
Slide 10: Potential Liquid Biopsy Global Market Opportunity
Pot e nt i al L i q u id Bio p sy Glo b al Ma r k e t Op p o r tu n ity
Slide 11: Liquid Biopsy market segments
Liquid Biopsy market segments Today Emerging Future Future Profiling Monitoring Companion Diagnostics Screening including detection of asymptomatic patients ~$9B worldwide market by 2020* ~$2B worldwide market by 2020* ~$5B worldwide market by 2020* ~$7B worldwide market by 2020* “We sized the [glob
Slide 12: Molecular Profiling of Cancer Biomarkers
Mole c ul a r Profi l ing of Canc e r Biomar k ers The Sta n d a rd of C a re in P e rso n a l iz e d T re a tme n t
Slide 13: Target Selector Biopsy
Target Selector Biopsy ctDNA CTCs Tissue Biopsy Personalized Molecular Assays Identification of Molecular Biomarkers Required to Qualify Patients for Targeted Therapy
Slide 14: Biocept: Completing the Answer
Biocept Completing the Answer™
Slide 15: 5-Year Relative Survival and Evolution of Targeted Therapies
5-Year Relative Survival By Year of Diagnosis (All Cancer Sites) 75.0% 70.0% 65.0% 60.0% 55.0% 50.0% 45.0% 40.0% 1975-1977 1978-1980 1981-1983 1987- 1989 1990-1992 1993-1995 1996-1998 1999-2001 2003-2006 2007-2013 2004 2013 the overall cancer death rate in the united stated fell by Evolution of Targ
Slide 16: Matching Cancer Patients to Personalized Therapy Remains Challenging
Matching Cancer Patients to Personalized Therapy Remains Challenging
Slide 17: Cost of ineffective treatment
Lives are lost… Cancer proliferates… Time elapses… Treatment effective Treatment not effective Treatment not effective Treatment effective Dollars are wasted… Resources spent… Time elapses…
Slide 18: Legacy Cancer Diagnostic Tools Do Not Tell The Complete Story
Advantages Disadvantages Cost Legacy Cancer Diagnostic Tools Do Not Tell The Complete Story
Slide 19: Biocept Solves the Problem by Combining the Best of Both Worlds
Bio c e p t So l v e s the Pro b l e m by Com b i n i n g the Be s t of B oth W o r l d s Target Selector Biopsy – Completing the Answer TM
Slide 20: Patient Case Study: The Gift of Time
Patient Case Study – Biocept’s Testing Provides “The Gift of Time” Biocept’s Target Selector Enables Personalized Treatment for Non-Small Cell Lung Cancer (NSCLC) Patient After Tissue Biopsy Proves Inadequate
Slide 21: Patient case timeline
Biopsy yields insufficient tissue for biomarker testing Jan 2014 Disease progression confirmed biopsy tissue insufficient for biomarker testing Nov 2014 Biocept’s liquid biopsy detects ALK Translocation Dec 1, 2014 Patient progresses liquid biopsy ordered Biocept liquid biopsy ordered again ALK not
Slide 22: Highly Relevant Test Menu
Cancer Target Selector CTC Target Selector ctDNA Hig h ly Rel e v a nt T e s t M e n u : In d ustry L e a d i n g Ass a y s T rust e d by C l i n ic i a n s, P a tie n ts, a n d P a y ers 15 Actionable Biomarkers Found in the Guidelines Breast HER2*, ER*, FGFR1, AR, PDL1, PR* ESR1 mutations Gastric
Slide 23: Industry-Leading Assay Performance
CTC Biomarkers + ctDNA Analytical Validation CTC Biomarkers + ctDNA Analytical Combined CTC Biomarkers + ctDNA Clinical Validation CTC Biomarkers + ctDNA Clinical Combined Industry-Leading Assay Performance Controlled Validation Concordance (standard criteria) – 99.3% Data Size (N) 4641 Accuracy 461
Slide 24: Premier Commercial Platform
Premier Commercial Platform
Slide 25: Commercial platform overview
Completing the answer Biocept 26 issued patents Comprehensive high- performance NCCN Test offering Evolution to Distributed Kit Model EmpowerTC tm Pathology partner ship Strong Growth Driven By Effective Commerical Team Increasing Reimbursement Opportunity for cost leadership
Slide 26: Differentiated Product Offerings
Company CTCs / Whole Cells ctDNA / DNA Fragments Proprietary Collection Tube Pathology Partnership Strategy Differentiated Product Offerings Genomic Health (GHDX)
Slide 27: Biocept IP Portfolio
Biocept IP Portfolio Family 1
Slide 28: Biocept: Completing the Answer
Biocept Completing the Answer™
Slide 29: Salesforce Coverage
Current Salesforce Coverage Sales Mgt. Sales Exec 14 NCCN Center direct sales representatives in the field Customer Focus ▪ Target select cancer center regions ▪ Focus on community oncologists (80% of cancer care) ▪ Partner with integrated delivery networks and local pathologists Commercial team ▪ E
Slide 30: Biocept: Completing the Answer
Biocept Completing the Answer™
Slide 31: AND Campaign Debut at ASCO 2017
“AND” Campaign Debut at ASCO 2017
Slide 32: Target Selector Liquid Biopsy AND campaign
Biocept Completing the Answer Target Selector TM Liquid Biopsy Increasing Targeted Therapies via Liquid Biopsy eating cancer patients, it’s no longer an either/or world. At Biocept, we’re all about the AND… It’s time to consider molecular information from both tissue AND blood. Biocept is the indust
Slide 33: EmpowerTC Launch at CAP 2017
EmpowerTC™ Launch at CAP 2017
Slide 34: EmpowerTC Tech-Only Liquid Biopsy
Biocept Compelting the Answer TM Empower TC TM Tech-Only Liquid Biopsy Empowering Local Pathologists With World-Class Diagnostics the first in the industry to offer cancer biomarker testing using both ctDNA AND CTCs. Biocept offers specialized tests for approved nccn biomarkers, including targeted t
Slide 35: Collaboration with Thermo Fisher Scientific
Collaboration with Thermo Fisher Scientific
Slide 36: Thermo Fisher Scientific Technology & Commercial Collaboration
Thermo Fisher scientific Agreement in Place for Technology & Commercial Collaboration biocept completing the answer ▪ Seek to Validate Thermo Fisher Oncomine™ NGS Panel in Biocept’s CLIA-certified laboratory ▪ Once validated, Biocept to be designated as Thermo Fisher Liquid Biopsy ―Center of Excelle
Slide 37: Health Plan Access Continues to Expand
Health Plan Access Continues to Expand with Third Party Contracts
Slide 38: Managed care agreements and payer networks
Multiplan imagine more… acpn America's Choice Provider Network fedmed bluecross blueshield stratose TM people analytics results medincrease health plans tm scripps three rivers trpn provider network galaxy health network fortified provider network biocept completing the answer ▪ Managed Care agreeme
Slide 39: Deploying Capital To Fuel Accelerated Growth
Deploying Capital To Fuel Accelerated Gro wth
Slide 40: Annual Revenue
Millions Annual Revenue $55 $5.0 $45 $40 $3.5 $3.0 $25 $20 S15 $10 $05 $0.0 $3.2 $5.1 FY 2017
Slide 41: Annual Revenue Development and Patient Samples
Annual Revenue Development Commercial$5.5 $5.0 $4.5 $4.0 $3.5 $3.0 $2.5 $2.0 $1.5 $1.0 $0.5 $0.0 FY 2014 $0.1 FY 2015 $0.6 FY 2016 $3.2 FY 2017 $5.1 Annual Patient Samples 5,500 5,000 4,500 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 0 FY 2014 661 FY 2015 2,030 FY 2016 4,540 FY 2017 5,051 Commerci
Slide 42: Execution of Value Creation Strategy
Biocept – Execution of Value Creation Strategy ▪ Investment in technology development of over $100M resulting in full commercialization ▪ Liquid Biopsy moving from early adopter orders to mainstream clinician orders for profiling. ▪ First liquid biopsy (plasma based EGFR testing) now in NCCN guideli
Slide 43: IVD kit development roadmap
Today Central Lab Collection Tube Commercialization Pathology Partnership 2018 IVD Kit Development 2019 Distributed IVD Kit Platform biocept completing the answer
Slide 44: Biocept: Completing the Answer
Biocept Completing the Answer™
Slide 45: Patented Target Selector Platform Enables both CTC and ctDNA Analysis
Patented Tar get Selector™ Platform Enables both CTC and ctDNA Analysis
Slide 46: CTC isolation and analysis workflow
Antibody Cocktail CTC Isolation CEE-Sure™ Blood Collection Tube for CTCs and ctDNA Patented Microfluidic Channel Detection, Enumeration and Biomarker Analysis all in the Channel FISH for Rearrangements Copy Number Variations ICC for Proteins Buffy Coat CTCS Plasma ctDNA Red Blood Cells Benefits: ▪ C
Slide 47: Patented Target Selector Platform Enables both CTC and ctDNA Analysis
Patented Target Selector™ Platform Enables both CT C and ctDNA Analysis Benefits:
Slide 48: ctDNA analysis workflow
Palsma ctdna buffy coat ctcs red blood cells DNA Isolation Patented Switch- Blocker Technology Multiplex Selector Enrichment PCR NGS Sanger Sequencing CEE-Sure™Blood Collection Tube for CTCs and ctDNA qPCR Mutation Detection ▪ Performing PCR upfront and then sequencing delivers added confidence to f
Slide 49: Biocept Publications, Posters, and Abstracts
Biocept Publications, Posters, and Abstracts
Slide 50: Scientific/Clinical Presentations
42 Scientific/Clinical Presentations ▪ 9 Peer-Reviewed Journal Publications and 3 Published Case Reports ▪ 23 Poster Presentations at Leading Scientific/Clinical Meetings ▪ 1 Technology Description ▪ 6 Abstracts: Scientific/Clinical Meetings
Slide 51: Journal publications
Journal of Thoracic Oncology ESMD == Clinics in Oncology FR
Slide 52: Partners in Establishing Clinical Utility
Partners in Establishing Clinical Utility ▪ Collaborations with major cancer centers
Slide 53: Medical meetings, KOL advisors and partnerships
▪ Participating in medical meetings and symposia ▪ Engaging KOL Advisors ▪ Building relationships with patient advocacy groups ▪ Expanding strategic partnerships with pharma and biotech for personalized diagnostics
Slide 54: Landmark Clinical Trial for Liquid Biopsy
Landmark Clinical Trial for Liquid Biopsy The Addario Lung Cancer Medical Institute (ALCMI) is an international research consortium driving clinical research via a world-class team of investigators from 25 member institutions in the U.S. UK, and Europe. It is supported by a dedicated centralized res
Slide 55: Achievements Since Going Public
Now At IPO Achievements Since Going Public ✓ Revenue of $5.1M in FY 2017 $0 Revenue ✓ In-house billing and collections Outsourced ✓ 26 Issued Patents ✓ 16 Members on Commercial Team (14 sales reps) None ✓ Multiple health plan agreements signed including BCBS plans covering over 200M lives None ✓ 4 P
Slide 56: Contact: Investor Relations
Contact: David Moskowitz, Investor Relations Email: dmoskowitz@biocept.com; Phone: 858-320-8244 Biocept
Slide 57: Biocept: Completing the Answer
Biocept Completing the Answer™